The U.S. Food and Drug Administration approved a 2 mg dose of Novo Nordisk’s Ozempic (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog indicated along with diet and exercise to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.
High Point, North Carolina-based vTv Therapeutics announced positive results from a mechanistic study of TTP399 in type 1 diabetes patients.
Many experts are convinced that Covid-19 can trigger the onset of diabetes – even in some adults and children who do not have the traditional risk factors.
Novo Nordisk will offer free, one-time supply of insulin to people in immediate need and at risk of rationing the medication.
Independent experts on an FDA advisory panel voted against the use of an already approved drug from Eli Lilly and Boehringer Ingelheim as an add-on to insulin therapy for type 1 diabetes.
Indianapolis-based Eli Lilly announced that the company’s Lispro Injection, an authorized generic version of the life-saving insulin Humalog, is available at pharmacies at a 50 percent lower list price.